Table 1 Demographic profile and characterization of adverse event reports of anti-IL-5 drugs

Indication

Asthma

20,886

73.34%

Unknown Indication

6356

22.32%

Other Indication

1236

4.34%

Reporter Type

Healthcare Professional

16,582

58.23%

Consumer

11,758

41.29%

Not Specified

138

0.48%

Gender

Male

7438

26.12%

Female

15,366

53.96%

Not Specified

5674

19.92%

Age

0–1 Month

8

0.03%

2 Months-2 Years

5

0.02%

3–11 Years

66

0.23%

12–17 Years

154

0.54%

18–64 Years

7387

25.94%

65–85 Years

4589

16.11%

More than 85 Years

211

0.74%

Not Specified

16,058

56.39%

Seriousness Criteria

Died

1555

5.46%

Life Threatening

366

1.29%

Hospitalised

8628

30.30%

Disabled

228

0.80%

Congenital Anomaly

70

0.25%

Required Intervention

12

0.04%